JP2010500291A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500291A5
JP2010500291A5 JP2009523112A JP2009523112A JP2010500291A5 JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5 JP 2009523112 A JP2009523112 A JP 2009523112A JP 2009523112 A JP2009523112 A JP 2009523112A JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5
Authority
JP
Japan
Prior art keywords
antibody
csfr
csf
pharmaceutical composition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009523112A
Other languages
English (en)
Japanese (ja)
Other versions
JP5235881B2 (ja
JP2010500291A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001127 external-priority patent/WO2008017126A1/en
Publication of JP2010500291A publication Critical patent/JP2010500291A/ja
Publication of JP2010500291A5 publication Critical patent/JP2010500291A5/ja
Application granted granted Critical
Publication of JP5235881B2 publication Critical patent/JP5235881B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009523112A 2006-08-11 2007-08-10 肺疾患病態の処理 Expired - Fee Related JP5235881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904378A AU2006904378A0 (en) 2006-08-11 Treatment and prophylaxis of pulmonary disease conditions
AU2006904378 2006-08-11
PCT/AU2007/001127 WO2008017126A1 (en) 2006-08-11 2007-08-10 Treatment of pulmonary disease conditions

Publications (3)

Publication Number Publication Date
JP2010500291A JP2010500291A (ja) 2010-01-07
JP2010500291A5 true JP2010500291A5 (https=) 2010-09-24
JP5235881B2 JP5235881B2 (ja) 2013-07-10

Family

ID=39032559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523112A Expired - Fee Related JP5235881B2 (ja) 2006-08-11 2007-08-10 肺疾患病態の処理

Country Status (10)

Country Link
US (2) US8574572B2 (https=)
EP (2) EP2526959B1 (https=)
JP (1) JP5235881B2 (https=)
AU (1) AU2007283463B2 (https=)
CA (1) CA2661446C (https=)
DK (1) DK2056858T3 (https=)
ES (1) ES2506065T3 (https=)
NZ (1) NZ574285A (https=)
PL (1) PL2056858T3 (https=)
WO (1) WO2008017126A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2567803C2 (ru) * 2009-07-31 2015-11-10 Дженентек, Инк. ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
PL2477656T3 (pl) 2009-09-15 2017-09-29 Csl Limited Leczenie stanów neurologicznych
US8980856B2 (en) * 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
JP6187777B2 (ja) * 2011-06-13 2017-08-30 シーエスエル、リミテッド G−csfrに対する抗体およびその使用
CA2986097A1 (en) * 2015-05-18 2016-11-24 The University Of British Columbia Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 CD11bアンタゴニストを含む劇症型急性肺炎治療用組成物
CA3081770A1 (en) 2017-11-29 2019-06-06 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
CN113272326B (zh) * 2018-12-04 2024-09-27 Csl创新私人有限公司 治疗嗜中性病症的方法
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
KR20260036321A (ko) 2023-07-05 2026-03-16 씨에스엘 이노베이션 피티와이 엘티디 겸상적혈구병의 합병증을 치료하거나 예방하는 방법

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2114015C (en) 1991-07-25 2002-12-10 Roland A. Newman Recombinant antibodies for human therapy
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20060093604A1 (en) 2002-08-23 2006-05-04 The Walter And Eliza Hall Institute Of Medical Research Method of treatment and prophylaxis
EP1841776B1 (en) 2005-01-13 2008-12-31 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Decladinosyl-macrolides with anti-inflammatory activity
WO2006077504A2 (en) 2005-01-18 2006-07-27 Koninklijke Philips Electronics N.V. An algorithm for growing 4-connected cores in image segmentation
WO2007084485A2 (en) 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases

Similar Documents

Publication Publication Date Title
JP2010500291A5 (https=)
Ng et al. Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway
JP2005530490A5 (https=)
JP2011500003A5 (https=)
JP2015519891A5 (https=)
JP2016116520A5 (https=)
JP2013504603A5 (https=)
JP2018126141A5 (https=)
JP2007505627A5 (https=)
JP2012505660A5 (https=)
JP2014511686A5 (https=)
JP2008546390A5 (https=)
JP2010528601A5 (https=)
JP2012505657A5 (https=)
JP2020500929A5 (https=)
JP2011516410A5 (https=)
JP2018510621A5 (https=)
ES3041629T3 (en) Method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5
JP2013537423A5 (https=)
JP2015511625A5 (https=)
JP2008525033A5 (https=)
Kay et al. Eosinophils and interleukin-5: the debate continues
CN115515560B (zh) 冠状病毒感染的治疗
JP2014504857A5 (https=)
CN112996913A (zh) 寡聚核酸分子及其应用